Open Access
Review

Table 1

- Current regimen of treatment for lung cancer.

Drug name Generic name Use
Xeloda Capecitabine anti-metabolites
Avastin Bevacizumab VEGF/VEGFR inhibitors
Tarceva Erlotinib EGFR inhibitors
Cytoxan Cyclophosphamide alkylating agents
Taxol Paclitaxel mitotic inhibitorsa
Taxotere Docetaxel mitotic inhibitors
Gemzar Gemcitabine antimetabolites
Erbitux Cetuximab EGFR inhibitors
Alimta Pemetrexed antimetabolites
Navelbine Vinorelbine mitotic inhibitors
Platinol Cisplatin alkylating agents
Trexall Methotrexate antimetabolites, antipsoriatics, antirheumatics
Ethyol Amifostine antineoplastic detoxifying agents
Iressa Gefitinib EGFR inhibitor
Neosar Cyclophosphamide alkylating agents
Platinol-AQ Cisplatin alkylating agents
Photofrin Porfimer miscellaneous antineoplastics
Onxol Paclitaxel mitotic inhibitors

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.